Perillaldehyde Attenuates Diabetic Nephropathy through Modulation of the Nrf2/Keap1 and NF‐κB Signalling Pathways
Cell Biology International · 2026-08 · 50 (8)
DOI: 10.1002/cbin.70193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, online erschienen am 06.08.2026. Verfasst von Harini Ramachandran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Kelch-Like ECH-Associated Protein 1, NF-E2-Related Factor 2, NF-kappa B. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a one of the common microvascular complication of diabetes that involves oxidative stress, inflammation, activation and overexpression of Nuclear factor kappa B (NF‐κB), and chronic renal dysfunction. In this study, we evaluated the renoprotective role of perillaldehyde (PA) in protecting kidneys from diabetic nephropathy using in vitro and in vivo models of Streptozotocin‐induced diabetic nephropathy. PA pre‐treatment of NRK‐52E cells under high‐glucose conditions resulted in a significant reduction of reactive oxygen species formation, up‐regulation of nuclear factor erythroid 2‐related factor 2 (Nrf2), suppression of Kelch‐like ECH‐associated protein 1 (Keap1), and elevation of antioxidant enzyme biomarkers, such as heme oxygenase 1, superoxide dismutase 1, and NAD(P)H dehydrogenase quinone 1. PA also inhibited the overexpression of NF‐κB, inducible nitric oxide synthase, and poly (ADP‐ribose) polymerase in high‐glucose exposed NRK‐52E cells. Administration of PA (35 and 70 mg/kg) to streptozotocin‐induced diabetic rats showed beneficial effects on renal function parameters such as creatinine and blood urea nitrogen. PA treatment attenuated glomerular and tubular structural damage, as evidenced by H&E and PAS staining. At molecular level, PA was found to maintain the redox balance in the kidneys by stimulating the Nrf2/Keap1/HO‐1 signalling pathway and inhibiting the NF‐κB‐dependent inflammatory response. Moreover, PA lowered lipid peroxidation and enhanced antioxidant status via reduction in MDA and elevation in GSH. The above results indicated that PA showed considerable reno‐protective actions through coordinated regulation of both oxidative stress and inflammation pathways in experimental models of diabetic nephropathy
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) SAS Nagar, Mohali, India.
ORCID-Profile: Ashutosh Kumar
Zitieren
APA
Ramachandran, H., Mourya, A. K., & Kumar, A. (2026). Perillaldehyde Attenuates Diabetic Nephropathy through Modulation of the Nrf2/Keap1 and NF‐κB Signalling Pathways. Cell Biology International, 50(8). https://doi.org/10.1002/cbin.70193
Vancouver
Ramachandran H, Mourya AK, Kumar A. Perillaldehyde Attenuates Diabetic Nephropathy through Modulation of the Nrf2/Keap1 and NF‐κB Signalling Pathways. Cell Biology International. 2026;50(8). doi:10.1002/cbin.70193
BibTeX
@article{Ramachandran2026,
author = {Ramachandran, Harini and Mourya, Akash Kumar and Kumar, Ashutosh},
title = {Perillaldehyde Attenuates Diabetic Nephropathy through Modulation of the Nrf2/Keap1 and NF‐κB Signalling Pathways},
journal = {Cell Biology International},
year = {2026},
volume = {50},
number = {8},
doi = {10.1002/cbin.70193}
}
EUVIMED